uracil and Rheumatoid Arthritis

uracil has been researched along with Rheumatoid Arthritis in 5 studies

2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder

Research

Studies (5)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percentage of Participants With American College of Rheumatology 20% (ACR20) Response at Week 12

ACR20 response: compared to baseline, greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >= 20% improvement in swollen joint count; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). (NCT00628095)
Timeframe: Week 12

C-Reactive Protein (CRP)

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

CE-224,535 Plasma Concentrations

Nominal times were used for summarizing the pharmacokinetic results (0 hours at randomization [Day 1] and Week 4 [pre-dose]; 1 hour at Week 2 [post-dose]; 2 hours at randomization [post-dose on Day 1]; and 3 hours at Week 2 [post-dose] and Week 4 [post-dose]). (NCT00628095)
Timeframe: 0 hour (pre-dose), 2 hours post-dose at Day 1; 1, 3 hours post-dose at Week 2; 0 hour (pre-dose), 3 hours post-dose at Week 4

Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])

DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (<=) 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission. (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0= least difficulty and 3= extreme difficulty. (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

Incidence of Withdrawal Due to Lack of Efficacy

Number of participants who withrew due to lack of efficacy were reported. (NCT00628095)
Timeframe: Week 2, 4, 8, 12, 14

Number of Tender/Painful and Swollen Joints

Number of tender/painful joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

Patient's Global Assessment of Arthritic Pain

Participants measured their pain at the time of assessment on a 0 to 100 mm VAS, with 0 mm= no pain and 100 mm= most severe pain. (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

Patient's Global Assessment of Arthritis

"Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 to 100 mm VAS, with 0 mm= very well and 100 mm= very poorly." (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

Percentage of Participants With American College of Rheumatology 20% (ACR20) Response at Week 2, 4 and 8

ACR20 response: compared to baseline, >=20% improvement in tender joint count; >= 20% improvement in swollen joint count; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). (NCT00628095)
Timeframe: Week 2, 4, 8

Percentage of Participants With American College of Rheumatology 50% (ACR50) Response

ACR50 response: compared to baseline, >=50% improvement in tender joint count; >= 50% improvement in swollen joint count; and >= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). (NCT00628095)
Timeframe: Week 2, 4, 8, 12

Percentage of Participants With American College of Rheumatology 70% (ACR70) Response

ACR70 response: compared to baseline, >=70% improvement in tender joint count; >= 70% improvement in swollen joint count; and >= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). (NCT00628095)
Timeframe: Week 2, 4, 8, 12

Physician Global Assessment (PGA) of Arthritis

Physician global assessment of arthritis was measured on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), with 0 mm= very good and 100 mm= very poor. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. (NCT00628095)
Timeframe: Baseline, Week 2, 4, 8, 12

Trials

2 trials available for uracil and Rheumatoid Arthritis

Other Studies

3 other studies available for uracil and Rheumatoid Arthritis